Table 3

%Studies that examined p53 sequence alterations included in the present meta-analysis

AuthorYearStageMethodExonMultiaNo. of patients
Horio et al. (73)1993I–IIISSCPX5–8bYes353649.3
Mitsudomi et al. (74)1993I–IVSSCPX5–8Yes516942.5
Carbone et al. (52)1994I–IIISSCPX4–8No383750.7
Kashii et al. (31)1995I–IVSSCPX5–9No317828.4
Mitsudomi et al. (7)1995I–IIISSCPX5–8ND448234.9
Kondo et al. (75)1996I–IIISSCPCodon 101–300No182442.9
Guangc et al. (76)1997I–IVSSCPX5–8ND377134.3
Ohno et al. (65)1997I–IIISSCP, seqX5–8No215328.4
Vega et al. (23)1997I–IVSSCP, seqX5–8No164625.8
Huang et al. (22)1998I–IIISSCP, seqX5–8No519335.4
Tomizawa et al. (72)1999ISSCP, seqX5–8ND396139
Topd et al. (77)1995I–IIIDGGE+ IHCX5–8, BP53-12, DO7ND371768.5
  • a Multivariate analysis.

  • b X, exons; ND, not done; seq, sequencing; DGGE, denaturing gradient gel electrophoresis.

  • c Analyzed disease-free survival.

  • d Examined both DNA and protein expression. Tumors with protein accumulation and/or sequence alteration were scored as abnormal.